A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 129
- 试验地点
- 2
- 主要终点
- Clinical Response
研究概览
简要总结
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
详细描述
This study is a randomized, sequential group, double-blind study. The first 60 subjects enrolled will be randomized to either 0.1% NVC-422 or 0.5% NVC-422. Randomization is 1:2 where 20 subjects will receive 0.1% NVC-422 and 40 subjects will receive 0.5% NVC-422. If there are no safety issues regarding the first 2 doses tested, the next 60 subjects will be randomized to either 0.1% or 1.5% NVC-422 with 20 subjects receiving 0.1% and 40 subjects receiving 1.5% NVC-422.
The lesion most representative of the subject's infection will be identified as the target lesion. This target lesion will be photographed, graded clinically, and its location recorded. At Visit 1, Screening and/or Baseline, a Gram stain will be performed to assess presence of Gram-positive cocci. If Gram-positive cocci are present, a swab for culture and sensitivity will be obtained. Treatment will began immediately after randomization.
Treatment will be 3 times per day (TID) for 7 consecutive days, following a morning, afternoon, and evening schedule.
After the start of treatment (Day 1), subjects will be assessed for safety on Day 4 (± 1). Clinical and bacteriological assessments of the target lesion will also occur on Day 8 (+1) and Follow-up on Day 15 (± 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be 2 - 12 years of age
- •Parents or Legal Guardians must sign a written informed consent document
- •Positive Gram stain of target lesion showing Gram-positive cocci;
- •Clinical diagnosis of primary non-bullous impetigo as per the protocol
- •Skin Infection Rating Scale total score of at least 4, with at least three of the five primary signs and symptoms present at baseline including a score of 1 or greater for exudate/pus;
- •Screening within one day of enrollment into the study.
排除标准
- •Presence of other skin diseases at or near the investigational target area to be treated;
- •Disease is so widespread or severe that, in the opinion of the investigator, oral antibiotic treatment is needed
- •Active impetigo lesions greater than 5 cm2
- •Signs and symptoms of a current infection requiring antibiotic treatment
- •Use of systemic or topical antibiotics or steroids within 72 hours prior to study entry
- •Females of childbearing potential
研究组 & 干预措施
NVC-422 Dermal Gel, 1.5%
干预措施: NVC-422 (Drug)
NVC-422 Dermal Gel, 0.5%
干预措施: NVC-422 (Drug)
NVC-422 Dermal Gel, 0.1%
干预措施: NVC-422 (Drug)
结局指标
主要结局
Clinical Response
时间窗: End of Treatment (Day 8) and Follow-up (Day 15)
Sufficient resolution of signs and symptoms of infection of the target lesion such that no additional antimicrobial therapy is required to treat the impetigo as evidenced by the SIRS score of 0 each for exudate/pus, crusting and pain and 0 or 1 each for erythema/inflammation and itching for a clinical success or a SIRS score of 0 for exudate/pus but does not meet all the criteria for clinical success for a clinical improvement.
次要结局
- Bacteriological Response(End of Treatment (Day 8) and Follow-up (Day 15))